May 11, 2020
Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampion(TM) for COVID-19 Patients
Apr 02, 2020
Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion(TM) to Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) featured in FOX News (VIDEO)
Feb 21, 2020
Ampio Provides Corporate Update
Dec 04, 2019
Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number
Oct 10, 2019
Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility
Sep 17, 2019
Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial
Aug 22, 2019
Ampio Pharmaceuticals Retains Financial Advisor and Appoints Transaction Advisory Committee
Jul 25, 2019
Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial
Jul 11, 2019
Ampio Appoints Moss Adams LLP as the Company's New Independent Auditor
Jul 10, 2019
Ampio Appoints Dan Stokely as the Company's new Chief Financial Officer
Jun 19, 2019
Ampio Pharmaceuticals Announces Closing of $12 Million Public Offering
Jun 14, 2019
Ampio Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Aug 27, 2018
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ampio Pharmaceuticals, Inc. To Contact The Firm
Aug 09, 2018
AMPIO INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Ampio Pharmaceuticals, Inc. To Contact The Firm
Aug 02, 2018
Ampio Pharmaceuticals, Inc. to Present at the 38th Annual Canaccord Genuity Growth Conference
Apr 20, 2018
Technical Perspectives on Biotech Stocks -- Alnylam Pharma, Amgen, Amicus Therapeutics, and Ampio Pharma
Mar 06, 2018
Ampio Hosting Conference Call, Wednesday, March 7, 5:00 pm EST
Jan 16, 2018
Ampio Update of J.P. Morgan Meeting Events and Disease Modification Discussions
Jan 08, 2018
Ampio Presentation at J.P. Morgan Healthcare Conference made available to all Shareholders
Dec 14, 2017
Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion(TM) in Severe Osteoarthritis-of-the Knee (OAK)